Navigation Links
Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility
Date:9/17/2008

New Facility Enables Pharmatek to Serve Growing Highly-Potent and Cytotoxic

Compound Market

SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Pharmatek -- a pharmaceutical chemistry development organization supporting the pharmaceutical industry -- today announced the opening of its highly-potent and cytotoxic facility located in San Diego.

The 18,000 sq. ft. facility includes newly constructed analytical and formulation development laboratories and cGMP manufacturing suites dedicated to the development of highly-potent and cytotoxic drug product for early phase clinical trials.

"Highly-potent and cytotoxic compounds are among the most sensitive drugs to handle and produce," said Kevin Rosenthal, director of manufacturing of Pharmatek. "Our primary goal when designing the facility was to optimize product quality while ensuring operator safety to guarantee our clients' drug candidates move smoothly from discovery to clinical trials."

The facility holds a State of California Food and Drug Branch (FDB) Drug Manufacturers License and is currently working on a number of highly-potent development projects. The FDB license authorizes Pharmatek to manufacture and ship clinical material from its state-of-the-art highly-potent and cytotoxic manufacturing and development site.

"The highly-potent facility is a significant addition to our service offering," said Timothy Scott, president of Pharmatek. "We are always looking for ways to better meet our client's drug development outsourcing needs, and the highly-potent and cytotoxic facility strengthens our ability to provide a broader level of services to our clients."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and highly-potent and cytotoxic drug development.

Statements contained in this media release which are not historical facts may

constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ

from those projected including sales forecasts and strategic expansion. The

trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry and

Pharmatek Formulation Screening are all property of Pharmatek Laboratories,

Inc. Additional information about Pharmatek Laboratories may be obtained at
the Web site http://www.pharmatek.com or by calling 858-805-6383.

Company Contact:

Elizabeth Hickman, Marketing Manager

Pharmatek Laboratories, Inc.

(858) 805-6383 x235

ehickman@pharmatek.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jeffrey A. Bibbs http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=48157 Timothy M. Scott http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=50335


'/>"/>
SOURCE Pharmatek
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration ... at the 5th Annual Marcum MicroCap Conference on Thursday, June ... at the Grand Hyatt Hotel. The Company,s presentation ... scheduled to begin at 11a.m ET in the Broadway Room. ... and outline milestones for the balance of 2016 and beyond. ...
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):